Brault Clément, Riis Anders H, Mor Anil, Duhaut Pierre, Thomsen Reimar W
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark,
Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, Amiens, France,
Clin Epidemiol. 2018 Oct 16;10:1533-1543. doi: 10.2147/CLEP.S158293. eCollection 2018.
It has been suggested that a hyper-effective immune system ("hyper-immunity") is central to the pathogenesis of giant cell arteritis and polymyalgia rheumatica (GCA/PMR). We examined if a low risk of infections, as a marker of hyper-immunity, can predict increased subsequent risk of GCA/PMR.
We conducted a population-based case-control study including all patients aged ≥50 years with incident GCA/PMR diagnosed between 1997 and 2012 in Northern Denmark. For each case, we selected 10 population controls matched on gender, age, place of residence, and time spent in the region. Complete history of hospital-treated infections and community-based anti-infective prescriptions was assessed in population-based registries. We used conditional logistic regression to compute OR of GCA/PMR associated with infections while adjusting for comorbidities, immunosuppressive treatment, and other potential confounders.
We included 7,225 GCA/PMR cases and 72,250 controls. When excluding all infections occurring within the last year before GCA/PMR diagnosis, there was no decreased risk for GCA/PMR in people with a history of hospital-treated infection (adjusted OR=1.04, 95% CI: 0.98-1.10) or community anti-infective treatment (adjusted OR=1.07, 95% CI: 0.99-1.16). Within the last year preceding the GCA/PMR index date, patients with hospital-treated infections (adjusted OR=1.59, 95% CI: 1.44-1.75) or community anti-infective treatment (adjusted OR=1.63, 95% CI: 1.48-1.79) had a greatly increased risk of a GCA/PMR diagnosis.
These results do not support the hypothesis of "hyper-immunity" leading to GCA/PMR. Instead, incident GCA/PMR is preceded by a slightly increased risk of infection, which may be related to protopathic bias or support theories that infections may be directly involved in the pathogenesis of GCA/PMR.
有人提出,高效免疫系统(“超免疫”)是巨细胞动脉炎和风湿性多肌痛(GCA/PMR)发病机制的核心。我们研究了作为超免疫标志物的低感染风险是否能预测随后GCA/PMR风险的增加。
我们进行了一项基于人群的病例对照研究,纳入了1997年至2012年在丹麦北部诊断为初发GCA/PMR的所有≥50岁患者。对于每例病例,我们选择10名在性别、年龄、居住地点和在该地区居住时间上匹配的人群对照。在基于人群的登记处评估医院治疗感染和社区抗感染处方的完整病史。我们使用条件逻辑回归来计算与感染相关的GCA/PMR的比值比,同时调整合并症、免疫抑制治疗和其他潜在混杂因素。
我们纳入了7225例GCA/PMR病例和72250名对照。在排除GCA/PMR诊断前最后一年内发生的所有感染后,有医院治疗感染史的人患GCA/PMR的风险没有降低(调整后的比值比=1.04,95%可信区间:0.98-1.10),接受社区抗感染治疗的人也是如此(调整后的比值比=1.07,95%可信区间:0.99-1.16)。在GCA/PMR索引日期前的最后一年内,有医院治疗感染史的患者(调整后的比值比=1.59,95%可信区间:1.44-1.75)或接受社区抗感染治疗的患者(调整后的比值比=1.63,95%可信区间:1.48-1.79)被诊断为GCA/PMR的风险大大增加。
这些结果不支持“超免疫”导致GCA/PMR的假说。相反,在发生GCA/PMR之前,感染风险略有增加,这可能与原发病偏倚有关,或支持感染可能直接参与GCA/PMR发病机制的理论。